StockData
Moderna, Inc. logo

Moderna, Inc.

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)

Close on Nov 2, 2026Market cap $88.16BP/E –Yield –

Moderna Actual GTN payments, credits and deductions applied by Year

Actual GTN payments, credits and deductions applied against reserves ($M) ($M)

Moderna Actual GTN payments, credits and deductions applied: $279M in FY2025, down 60.4% from a year earlier.

Latest, FY2025
279
Period ended Dec 31, 2025
Change on a year earlier
-60.4%
704 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-20) ↗

Reported in Form 10-Q / 10-K Note 2 (Sales Returns Reserve Rollforward).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedActual GTN payments, credits and deductions applied against reserves ($M) ($M)Year on yearSource
FY2025Dec 31, 2025279-60.4%Form 10-K (filed 2026-02-20) ↗
FY2024Dec 31, 2024704-73.0%Form 10-K (filed 2025-02-21) ↗
FY2023Dec 31, 20232,608-61.0%Form 10-K (filed 2024-02-23) ↗
FY2022Dec 31, 20226,683-24.7%Form 10-K (filed 2023-02-24) ↗
FY2021Dec 31, 20218,872+5,190.4%Form 10-K (filed 2022-02-25) ↗
FY2020Dec 31, 2020168–Form 10-K (filed 2021-02-26) ↗

Breakdown

What makes up actual GTN payments, credits and deductions applied

Cite this data

StockData. (2026). Moderna Actual GTN payments, credits and deductions applied ($M), annual FY2020–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/gtn-deductions-paid

See every metric in the Moderna KPI table. Data updated Nov 3, 2026.